← Library
Prescription-only medicine. This page is educational information only. Do not use without a licensed prescriber.
IndexedBuilt automatically from public databases on 2026-09-30. Not yet hand-reviewed by PLOBT.How this works →

Aprotinin

FDA approved · Rx

Serine protease inhibitor

Also known as: Trasylol, BPTI, Riker 52G, Antilysine, Aprotinina, Aprotinine, Aprotininum, Antikrein

Evidence score
88/ 100
Strong evidence

Strong, human-grade evidence

  • Regulatory standing. FDA-approved prescription medicine
  • Human trials. Backed by controlled human studies
  • Registered human trials. 33 registered studies on ClinicalTrials.gov, most advanced Phase 4
  • 1 cited source. Includes primary / regulatory sources

Computed with the same four public criteria as every profile. The human-evidence grade on an indexed profile is set automatically and may change when it is hand-reviewed. It is not a safety score, not a purity rating, and not medical advice, and not a claim that this compound treats, cures, or prevents any condition.

What it is

Aprotinin, known by the brand name Trasylol, is a small protein originally isolated from cow lung and pancreas tissue. It blocks several serine proteases, including plasmin and kallikrein, which slows the breakdown of blood clots and dampens inflammatory pathways activated during surgery.

What the evidence shows

Automatic summaryHuman trials

Aprotinin was approved in the United States for reducing blood loss and transfusion need in certain heart bypass surgeries. US marketing was suspended in 2007 to 2008 after safety concerns, including a large trial signaling higher mortality than alternatives. Its current US status is unclear, and the gathered database facts did not confirm an active FDA approval, although some other regions later allowed restricted use.

Key facts

Molecular formula
C284H432N84O79S7
Molecular weight
6511 g/mol

Registered human trials

Live from ClinicalTrials.gov, refreshed daily.

33registered studies
Phase 4most advanced phase
19completed (sample)
1recruiting (sample)

Fibrin Sealant Vascular Surgery Study

Phase 2CompletedNCT00576420

FS VH S/D 500 S-apr in Vascular Surgery

Phase 3CompletedNCT00892957

Study to Investigate the Effect of Aprotinin of Transfusion Requirements in Patients Undergoing Surgical Procedures for Lung or Esophageal Cancer

Phase 3TerminatedNCT00306137

Fibrin Sealant for Cholangiotomy Closure Study

Phase 2UnknownNCT02545153

Published literature

Live from Europe PMC. This is how much has been published, not how much is proven in humans.

4,765papers referencing Aprotinin

Thrombolysis in Myocardial Infarction (TIMI) Trial--phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase.

J Am Coll Cardiol1988

Dramatic aggregation of Alzheimer abeta by Cu(II) is induced by conditions representing physiological acidosis.

J Biol Chem1998

Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor beta(1).

J Exp Med2001

Tranexamic acid: a review of its use in surgery and other indications.

Drugs1999

Sources

Risks, side effects and study doses are only published on hand-reviewed profiles. Want this one reviewed, or spotted something wrong? Tell us.